Professor Nigel Wheeldon
MB, ChB, MD, FRCP, FESC
Clinical Medicine, School of Medicine and Population Health
Honorary Professor of Inherited Cardiac Conditions
+44 114 305 5021
Full contact details
Clinical Medicine, School of Medicine and Population Health
Department of Cardiothoracic Surgery
Sheffield Teaching Hospitals NHS Trust
Northern General Hospital, Herries Road
Sheffield
S5 7AU
- Profile
-
For enquiries, please contact – iicd-om-operational@sheffield.ac.uk
I am Lead Consultant Cardiologist for the Regional Inherited Cardiac Conditions Service in Sheffield and Honorary Professor of Inherited cardiac conditions at the University of Sheffield. I started the Regional Inherited Cardiac Conditions Service 20 years ago and it is one of the largest and most comprehensive ICC services in the UK.
This sees patients with cardiomyopathies, inherited arrhythmia, families afflicted by SADS, inherited aortovascular disease, neuromuscular disorders and familial hypercholesterolaemia. Sheffield is one of only two designated Ehlers Danlos Diagnostic centres and I run a dedicated vascular EDS clinic. I also have a joint Sheffield/Birmingham Fabry disease service.
I am the founder of the UK Association for Inherited Cardiac Conditions (AICC). I have a longstanding association with the Far East and have visited hospitals and institutions across Asia for many years, giving lectures and being involved in patient care.
I received an Honorary Professorship from the Peoples Hospital, Peking University, Beijing and Visiting Professorship from Dalian Medical University. I am an International Fellow of the Hong Kong College of Cardiology. In addition, I am a qualified Commercial Pilot, Flight Instructor and Examiner. In 2007, I piloted aeroplanes worldwide on a 3 month venture called Flight for Hearts to lecture and raise awareness of inherited cardiac conditions.
- Research interests
-
My research interests are Inherited Cardiac Conditions (ICCs). Sudden unexplained cardiac death is now known in many cases to have a genetic basis, with major implications for family members. Individual disorders are unusual, with many physicians having limited experience of these conditions.
However, collectively they are common and huge advances in genetic testing technology have allowed otherwise unidentified clinical syndromes to become recognised. A substantial number of subclinical cases are present in the general population, some of whom are at risk.
Whilst seemingly heterogeneous, patients with cardiomyopathy, inherited arrhythmia, and inherited aortovascular disease are a remarkably similar population. The conditions are largely monogenic, they typically affect younger people, have major family implications and may carry significant cardiac risk. Genetic testing is now available for many ICCs and potentially life-saving treatments available.
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI). Circulation, 138(13), 1290-1300. View this article in WRRO
- Globotriaosylsphingosine (Lyso-Gb3) as a biomarker for cardiac variant (N215S) Fabry disease. Journal of Inherited Metabolic Disease, 41(2), 239-247.
- Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 175(1), 40-47.
- The 2017 international classification of the Ehlers-Danlos syndromes. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 175(1), 8-26.
- Diagnostic yield of molecular autopsy in patients with sudden arrhythmic death syndrome using targeted exome sequencing. Europace, 18(6), 888-896.
- Outcomes of Primary Percutaneous Coronary Intervention for Patients
with Previous Coronary Artery Bypass Grafting Presenting with STsegment
Elevation Myocardial Infarction. The Open Cardiovascular Medicine Journal, 9(1), 99-104. View this article in WRRO
All publications
Journal articles
- Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI). Circulation, 138(13), 1290-1300. View this article in WRRO
- Globotriaosylsphingosine (Lyso-Gb3) as a biomarker for cardiac variant (N215S) Fabry disease. Journal of Inherited Metabolic Disease, 41(2), 239-247.
- Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 175(1), 40-47.
- The 2017 international classification of the Ehlers-Danlos syndromes. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 175(1), 8-26.
- Diagnostic yield of molecular autopsy in patients with sudden arrhythmic death syndrome using targeted exome sequencing. Europace, 18(6), 888-896.
- Outcomes of Primary Percutaneous Coronary Intervention for Patients
with Previous Coronary Artery Bypass Grafting Presenting with STsegment
Elevation Myocardial Infarction. The Open Cardiovascular Medicine Journal, 9(1), 99-104. View this article in WRRO
- Spontaneous coronary artery dissection. General Thoracic and Cardiovascular Surgery, 57(10), 540-543.
- Anemia, hypoalbuminemia, and renal impairment as predictors of bleeding complications in patients receiving anticoagulation therapy for nonvalvular atrial fibrillation: A secondary analysis. Clinical Therapeutics, 31(7), 1534-1539.
- Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice. The American Journal of Geriatric Pharmacotherapy, 6(1), 1-11.
- ANTICOAGULATION OF ATRIAL FIBRILLATION IN OLDER PEOPLE: A CLINICAL PRACTICE OBSERVATIONAL STUDY. Journal of the American Geriatrics Society, 54(1), 176-177.
- Active inflammatory bowel disease and coronary artery dissection. Postgraduate Medical Journal, 81(951), 68-70.
- Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic. Clinical Therapeutics, 26(9), 1470-1478.
- Use of resources and cost implications of stroke prophylaxis with warfarin for patients with nonvalvular atrial fibrillation. The American Journal of Geriatric Pharmacotherapy, 1(2), 53-60.
- A Formulary Analysis of Angiotensin II Antagonists in a UK Teaching Hospital. Disease Management & Health Outcomes, 10(6), 355-362.
- Pharmacologic prevention of acute ischemic complications of coronary angioplasty. Catheterization and Cardiovascular Diagnosis, 42(3), 249-256.
- Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale. Cardiovascular Research, 33(1), 201-208.
- Coronary heart disease and atrial fibrillation. BMJ, 312(7031), 641-641.
Conference proceedings papers
- 4 years' cascade genetic testing for familial hypercholesterolaemia in England – Increased referrals and ascertainment. Atherosclerosis, Vol. 255 (pp 3-3)
- 27 Impact of Culprit Versus Non-Culprit Angiography Strategy on Primary PCI Door to Balloon Times. Heart, Vol. 102(Suppl 6) (pp A18-A18)
- PCV29 USE OF RESOURCES AND COST IMPLICATIONS OF STROKE PROPHYLAXIS WITH WARFARIN FOR PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION. Value in Health, Vol. 6(6) (pp 653-654)
- Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI). Circulation, 138(13), 1290-1300. View this article in WRRO
- Teaching interests
-
I teach on MBChB at the University of Sheffield and co-lead and teach on a final year UG module ‘Cardiovascular Pharmacology’ (CDL301) for Biomedical Science Students.
- Professional activities and memberships
-
- Department of Health NSF Chapter 8 group
- Representative for inherited cardiac conditions on the NHS England Clinical Reference Group